Kyverna Therapeutics Inc
KYTX
Company Profile
Business description
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Contact
5980 Horton Street
Suite 550
EmeryvilleCA94608
USAT: +1 510 925-2492
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
130
Stocks News & Analysis
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
stocks
After earnings, is Amazon a buy, a sell, or fairly valued?
After the launch of Amazon Supply Chain Services, here’s what we think of the stock.
stocks
ASX retail share expected to recover despite choppy conditions
Weakening consumer demand a temporary headwind for ASX retailer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,942.40 | 14.50 | 0.16% |
| CAC 40 | 8,030.54 | 82.03 | -1.01% |
| DAX 40 | 24,291.92 | 46.71 | -0.19% |
| Dow JONES (US) | 49,609.16 | 12.19 | 0.02% |
| FTSE 100 | 10,242.58 | 9.51 | 0.09% |
| HKSE | 26,406.84 | 13.13 | 0.05% |
| NASDAQ | 26,247.08 | 440.88 | 1.71% |
| Nikkei 225 | 62,417.88 | 295.77 | -0.47% |
| NZX 50 Index | 13,210.48 | 35.35 | 0.27% |
| S&P 500 | 7,398.93 | 61.82 | 0.84% |
| S&P/ASX 200 | 8,701.80 | 11.50 | 0.13% |
| SSE Composite Index | 4,225.02 | 45.07 | 1.08% |